Table 2.
Main effects of TAVI vs. SAVR for specific complications
| AUTOR, YEAR | MAJOR BLEEDING | AKI | VASCULAR COMPLICATION | PACEMAKER IMPLANTATION | RESIDUAL AORTIC REGURGITATION | NEW-ONSET ATRIAL FIBRILLATION | MODERATE-SEVERE PARAVALVULAR LEAK | ATRIAL FIBRILLATION |
|---|---|---|---|---|---|---|---|---|
| Wu YC, 2013 | = (REOPERATION) | - | - | + | ||||
| Panchal, 2013 | + | |||||||
| Nagaraja V, 2014 | = | - | - | + | - | |||
| Khan AR, 2016 | + | - | - | - | ||||
| Villablanca PA, 2016 | + | + | - | - | - | + | ||
| Carnero-Alcázar M, 2017 | + | + | - | - | - | |||
| Wang Y, 2018 | + | + | - | + | ||||
| Cheng X, 2019 | + (CKD) | = (CKD) | - (CKD) | |||||
| Ueshima D, 2019 | - (men) | |||||||
| Ueshima D, 2019 | + | - | - | - | ||||
| Al-Abdouh A, 2020 | + | + | - | + | - | |||
| Hofer F, 2020 | + | + | - | + | ||||
| Goel S, 2020 | = | - | + | |||||
| Kundu A, 2020 | + | + | - | + | ||||
| Vipparthy SC, 2020 | + | - | - | + | ||||
| Lou Y, 2020 | + | + | - | - | - | - | + | |
| Zhang D, 2020 | + | = | - | - | + | |||
| Ueyama H, 2020 | - | |||||||
| D’Ascenzo F, 2021 | + | + | + | |||||
| Matsuda Y, 2021 | ||||||||
| Chen CG, 2022 | + | + | - | + | ||||
| Sá Pompeu M, 2022 | + | - | - | |||||
| Ion AC, 2022 | ||||||||
| Sakurai Y, 2022 | = | + | - | - | ||||
| Barili F, 2022 | ||||||||
| Ahmad Y, 2023 | - | - | + | + | - | |||
| Lerman, 2023 | + | + | - | - | + | |||
| Yokoyama, 2023 |
+ (0–1 years) + (1–2 years) = (2–5 years) |
|||||||
| Tariq, 2023 | = | + |
“+” TAVI has a significant better effect than SAVR technique, “=” there is no significant difference between TAVI and SAVR, “-“there is a significant worse effect than SAVR